Back to search results

Monitoring Troponin During Immune Checkpoint Therapy

This study, called STRICT, is looking at whether regularly checking a heart injury marker called troponin in your blood can help reduce heart-related side effects when you're receiving immune checkpoint therapy for cancer. You would have your troponin levels checked before each immune checkpoint inhibitor infusion for the first 12 weeks of your treatment. The study aims to see if this monitoring can decrease serious heart problems like myocarditis (inflammation of the heart muscle) or heart failure. To join, you need to be at least 18 years old and planning to receive immune checkpoint therapy. The study is currently unclear on its recruitment status and plans to enroll 980 participants.

Study design
This is an interventional study planning to enroll 980 participants. It compares troponin surveillance with standard of care.
What's involved
You would have your troponin levels monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy. If symptoms arise, you would receive standard of care with cardiac evaluations.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06337097

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

Recruiting
NAAges 18+InterventionalScreening
M.D. Anderson Cancer Center
~980 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Troponin surveillanceStandard of care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year.

Conditions

Immune Checkpoint Therapy

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Nicolas Palaskas, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Nicolas Palaskas, MD
[email protected]
(713) 606-3957
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female patient ≥18 years old
Plan for treatment with an immune checkpoint inhibitor as standard of care even if patient is also on an additional investigational cancer therapeutic
Willingness to provide informed consent

Exclusion

Troponin T not available at screening or prior to randomization
Inability to comply with planned study procedures
Major adverse cardiovascular event included in the primary outcome within the 30 days prior to enrollment
Any medical condition that could interfere with, or for which the treatment might interfere with the conduct of the study or interpretation of the study results, or that would, in the opinion of the investigator, increase the risk of the participant by participating in the study
Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)